|Articles|April 15, 2002
Potential treatment: Miravant regains rights to wet AMD therapy
Santa Barbara, CA-Miravant Medical Technologies plans to seek new applications for its primary drug candidate, a potential therapy for wet age-related macular degeneration (AMD)
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
4
Port Delivery System Therapies in Retinal Vascular Diseases
5


















